144 related articles for article (PubMed ID: 38732027)
1. Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA.
Leckie J; Yokota T
Molecules; 2024 Jun; 29(11):. PubMed ID: 38893532
[TBL] [Abstract][Full Text] [Related]
2. Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.
Oliveira Santos M; de Carvalho M
Expert Rev Neurother; 2024 Jun; 24(6):549-553. PubMed ID: 38758193
[TBL] [Abstract][Full Text] [Related]
3. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis.
Nishimura AL; Mitne-Neto M; Silva HC; Richieri-Costa A; Middleton S; Cascio D; Kok F; Oliveira JR; Gillingwater T; Webb J; Skehel P; Zatz M
Am J Hum Genet; 2004 Nov; 75(5):822-31. PubMed ID: 15372378
[TBL] [Abstract][Full Text] [Related]
4. Medicinal Chemistry of Antisense Oligonucleotides for Therapeutic Use in SARS-CoV-2: Design Strategies and Challenges for Targeted Delivery.
Nedaeinia R; Ranjbar M; Goli M; Etebari M; Safabakhsh S; Bayram H; Ferns GA; Tehrani HM; Salehi R
Curr Med Chem; 2024 Jun; ():. PubMed ID: 38860908
[TBL] [Abstract][Full Text] [Related]
5. Antisense Oligonucleotides for Rapid Translation of Gene Therapy in Glioblastoma.
Desgraves JF; Mendez Valdez MJ; Chandar J; Gurses ME; Henderson L; Castro JR; Seetheram D; Ivan ME; Komotar RJ; Shah AH
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792022
[TBL] [Abstract][Full Text] [Related]
6. Enhancing Clinical Infrastructure for the Delivery of Intrathecal and Genetic Therapies: A Qalsody (Tofersen) Model for Patients With
Morganroth J; Bardakjian TM; Dratch L; Quinn CC; Elman LB
Neurol Clin Pract; 2024 Aug; 14(4):e200303. PubMed ID: 38855716
[TBL] [Abstract][Full Text] [Related]
7. Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights.
Ersöz E; Demir-Dora D
Drug Dev Res; 2024 Jun; 85(4):e22187. PubMed ID: 38764172
[TBL] [Abstract][Full Text] [Related]
8. Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade.
Cantara S; Simoncelli G; Ricci C
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732027
[TBL] [Abstract][Full Text] [Related]
9. Effects of tofersen treatment in patients with
Wiesenfarth M; Dorst J; Brenner D; Elmas Z; Parlak Ö; Uzelac Z; Kandler K; Mayer K; Weiland U; Herrmann C; Schuster J; Freischmidt A; Müller K; Siebert R; Bachhuber F; Simak T; Günther K; Fröhlich E; Knehr A; Regensburger M; German A; Petri S; Grosskreutz J; Klopstock T; Reilich P; Schöberl F; Hagenacker T; Weyen U; Günther R; Vidovic M; Jentsch M; Haarmeier T; Weydt P; Valkadinov I; Hesebeck-Brinckmann J; Conrad J; Weishaupt JH; Schumann P; Körtvélyessy P; Meyer T; Ruf WP; Witzel S; Senel M; Tumani H; Ludolph AC
EClinicalMedicine; 2024 Mar; 69():102495. PubMed ID: 38384337
[TBL] [Abstract][Full Text] [Related]
10. The sense of antisense therapies in ALS.
Van Daele SH; Masrori P; Van Damme P; Van Den Bosch L
Trends Mol Med; 2024 Mar; 30(3):252-262. PubMed ID: 38216448
[TBL] [Abstract][Full Text] [Related]
11. Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders.
Lauffer MC; van Roon-Mom W; Aartsma-Rus A;
Commun Med (Lond); 2024 Jan; 4(1):6. PubMed ID: 38182878
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Therapies of Spinal Muscular Atrophy: A Narrative Review of Preclinical, Clinical-Experimental, and Real-World Evidence.
Crisafulli S; Boccanegra B; Vitturi G; Trifirò G; De Luca A
Brain Sci; 2023 Oct; 13(10):. PubMed ID: 37891814
[TBL] [Abstract][Full Text] [Related]
13. Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit.
Sattler R; Traynor BJ; Robertson J; Van Den Bosch L; Barmada SJ; Svendsen CN; Disney MD; Gendron TF; Wong PC; Turner MR; Boxer A; Babu S; Benatar M; Kurnellas M; Rohrer JD; Donnelly CJ; Bustos LM; Van Keuren-Jensen K; Dacks PA; Sabbagh MN;
Neurol Ther; 2023 Dec; 12(6):1821-1843. PubMed ID: 37847372
[TBL] [Abstract][Full Text] [Related]
14. The pathogenic mechanism of TAR DNA-binding protein 43 (TDP-43) in amyotrophic lateral sclerosis.
Wang X; Hu Y; Xu R
Neural Regen Res; 2024 Apr; 19(4):800-806. PubMed ID: 37843214
[TBL] [Abstract][Full Text] [Related]
15. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study.
Crawford TO; Swoboda KJ; De Vivo DC; Bertini E; Hwu WL; Finkel RS; Kirschner J; Kuntz NL; Nazario AN; Parsons JA; Pechmann A; Ryan MM; Butterfield RJ; Topaloglu H; Ben-Omran T; Sansone VA; Jong YJ; Shu F; Zhu C; Raynaud S; Lago TR; Paradis AD; Foster R; Chin R; Berger Z;
Muscle Nerve; 2023 Aug; 68(2):157-170. PubMed ID: 37409780
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of
Baughn MW; Melamed Z; López-Erauskin J; Beccari MS; Ling K; Zuberi A; Presa M; Gonzalo-Gil E; Maimon R; Vazquez-Sanchez S; Chaturvedi S; Bravo-Hernández M; Taupin V; Moore S; Artates JW; Acks E; Ndayambaje IS; Agra de Almeida Quadros AR; Jafar-Nejad P; Rigo F; Bennett CF; Lutz C; Lagier-Tourenne C; Cleveland DW
Science; 2023 Mar; 379(6637):1140-1149. PubMed ID: 36927019
[TBL] [Abstract][Full Text] [Related]
17. Chemistry, structure and function of approved oligonucleotide therapeutics.
Egli M; Manoharan M
Nucleic Acids Res; 2023 Apr; 51(6):2529-2573. PubMed ID: 36881759
[TBL] [Abstract][Full Text] [Related]
18. SYF2 suppression mitigates neurodegeneration in models of diverse forms of ALS.
Linares GR; Li Y; Chang WH; Rubin-Sigler J; Mendonca S; Hong S; Eoh Y; Guo W; Huang YH; Chang J; Tu S; Dorjsuren N; Santana M; Hung ST; Yu J; Perez J; Chickering M; Cheng TY; Huang CC; Lee SJ; Deng HJ; Bach KT; Gray K; Subramanyam V; Rosenfeld J; Alworth SV; Goodarzi H; Ichida JK
Cell Stem Cell; 2023 Feb; 30(2):171-187.e14. PubMed ID: 36736291
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
